South San-Francisco-based Structure’s obesity pill results rival Novo, Lilly treatments

The drug’s efficacy “looks to be highly competitive” and potentially better than rival pills from Novo and Lilly, BMO Capital ...

Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong cash runway.

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...
Clinical Trials Arena on MSN

Structure’s obesity pill prompts 16.3% weight loss in Phase II

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.
BioPharma Dive

Structure’s GLP-1 pill shows ‘best-in-class’ potential in obesity trial

Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...
FierceBiotech

In Structure licensing deal, Roche commits $100M to shore up GLP-1 position

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics. The agreement grants Roche and ...